Intra-articular Histone Deacetylase Inhibitor Microcarrier Delivery to Reduce Osteoarthritis.
Jing YeRonghui DengXinjie WangShitang SongXiong XuJi-Ying ZhangBing-Bing XuXing WangJia-Kuo YuPublished in: Nano letters (2023)
The histone deacetylase inhibitor (HDACi) was a milestone in the treatment of refractory T-cell lymphoma. However, the beneficial effects of HDACi have not been appreciated in osteoarthritis (OA). Herein, we implemented a microcarrier system because of the outstanding advantages of controlled and sustained release, biodegradability, and biocompatibility. The poly(d,l-lactide- co -glycolide) (PLGA) microcapsules have a regulated and sustained release profile with a reduced initial burst release, which can improve the encapsulation efficiency of the Chidamide. The emulsion solvent evaporation strategy was used to encapsulate Chidamide in PLGA microcapsules. The encapsulation of Chidamide was established by UV-vis spectra and scanning electron microscopy. Additionally, the inhibition of Tnnt3 and immune stimulation by Chidamide helped to inhibit cartilage destruction and prevent articular cartilage degeneration. Based on the results, the Chidamide in PLGA microcapsules provides a transformative therapeutic strategy for the treatment of osteoarthritis patients to relieve symptoms and protect against cartilage degeneration.
Keyphrases
- histone deacetylase
- electron microscopy
- drug delivery
- knee osteoarthritis
- rheumatoid arthritis
- end stage renal disease
- drug release
- newly diagnosed
- extracellular matrix
- prognostic factors
- depressive symptoms
- peritoneal dialysis
- physical activity
- high frequency
- bone regeneration
- patient reported outcomes
- sleep quality
- density functional theory
- molecular dynamics
- aqueous solution